Viewing Study NCT03207867

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:46 AM
Ignite Modification Date: 2026-01-05 @ 9:49 PM
Study NCT ID: NCT03207867
Status: TERMINATED
Last Update Posted: 2024-10-09
First Post: 2017-06-19
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None NSCLC, Non Small Cell Lung Cancer View
None RCC, Renal Cell Cancer View
None Pancreatic Cancer View
None Urothelial Cancer View
None Head and Neck Cancer View
None DLBCL, Diffused Large B Cell Lymphoma View
None MSS, Microsatellite Stable Colon Cancer View
None TNBC, Triple Negative Breast Cancer View
None Melanoma View
None mCRPC, Metastatic Castration Resistant Prostate Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunotherapy View
None A2aR View
None PDR001 View
None NIR178 View
None NSCLC View
None solid tumors View